Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Targets |
IRE1/XBP1s
|
---|---|
ln Vitro |
IXA4 (10 μM; 4 hours) selectively upregulates the mRNA of XBP1 in other cell lines, such as Huh7 and SHSY5Y cells, in comparison to genes regulated by ATF6 (e.g., BiP) or PERK (e.g., CHOP)[1].
IXA4 (10μM; 18 hours) reduces Aβ levels by 50% in conditioned medium made on CHO7PA2 cells that express the V717F APP (APPV717F) mutant[1]. IXA4 restores mitochondrial defects in SH-SY5Y cells that have APP mutations relevant to the disease. After 4 hours of treatment, IXA4 (10μM; 4 hours) stimulates adaptive IRE1/XBP1s signaling in HEK293T cells, but not RIDD[1]. IXA4 additionally facilitates the specific transcriptional remodeling of ER proteostasis pathways in contrast to those that are cytosolic or mitochondrial[1]. |
References |
Molecular Formula |
C24H28N4O4
|
---|---|
Molecular Weight |
436.512
|
Exact Mass |
436.21
|
Elemental Analysis |
C, 66.04; H, 6.47; N, 12.84; O, 14.66
|
CAS # |
1185329-96-7
|
Related CAS # |
1185329-96-7
|
PubChem CID |
26357859
|
Appearance |
White to off-white solid powder
|
LogP |
2.7
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
5
|
Rotatable Bond Count |
11
|
Heavy Atom Count |
32
|
Complexity |
576
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
ZVSKMVAWWBSNOY-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C24H28N4O4/c1-19-8-10-22(11-9-19)32-15-13-27(2)24(30)18-28-17-20(16-25-28)26-23(29)12-14-31-21-6-4-3-5-7-21/h3-11,16-17H,12-15,18H2,1-2H3,(H,26,29)
|
Chemical Name |
N-[1-[2-[methyl-[2-(4-methylphenoxy)ethyl]amino]-2-oxoethyl]pyrazol-4-yl]-3-phenoxypropanamide
|
Synonyms |
IXA4; IXA 4; IXA-4
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 87~100 mg/mL (199.3~229.1 mM)
Ethanol: ~11 mg/mL (~25.2 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2909 mL | 11.4545 mL | 22.9090 mL | |
5 mM | 0.4582 mL | 2.2909 mL | 4.5818 mL | |
10 mM | 0.2291 mL | 1.1454 mL | 2.2909 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Transcriptional profiling of compounds IXA1, IXA4, and IXA6 shows preferential induction of IRE1/XBP1s target genes. Nat Chem Biol . 2020 Oct;16(10):1052-1061. td> |
Compounds IXA4 and IXA6 show selectivity for IRE1/XBP1s-dependent ER proteostasis remodeling. Nat Chem Biol . 2020 Oct;16(10):1052-1061. td> |
Compound IXA4 increases degradation of amyloid precursor protein (APP) mutants. Nat Chem Biol . 2020 Oct;16(10):1052-1061. td> |
The IRE1/XBP1s activator IXA4 rescues mitochondrial defects in SH-SY5Y cells expressing disease-relevant APP mutants. Nat Chem Biol . 2020 Oct;16(10):1052-1061. td> |